NEW ORLEANS — Esperion Therapeutics’ (ESPR) experimental cholesterol drug, bempedoic acid, reduced low-density-lipoprotein cholesterol by more than 17 percent in 12 weeks and sustained those results for a full year, according to new data presented at the annual meeting of the American College of Cardiology Monday.

Those results are roughly consistent with previous studies of the drug, which is currently being reviewed by the Food and Drug Administration. But both investors and doctors will likely still have questions about side effects and safety.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy